|
GIP-C34
is a novel oncology therapeutic lead compound that works on the
principle of cell cycle control. This peptide utilizes a unique
natural mechanism of action related to S-phase arrest (US Patents
5,674,842 and 5,707,963).
CRPC-L09
is a set of compounds that have demonstrated in vitro ability to
down regulate the AR pathway, having potential as a therapeutic
for Castration Resistant Prostate Cancer.
MET2-L14
is a novel oncology therapeutic lead compound that has been discovered
to have strong anti-metastatic properties. This compound has demonstrated
in vitro regulatory activity for dissociation, migration, cell adhesion,
invasion and proliferation (US and International Patents Pending).
RDS1-L12
is a novel DNA Repair Inhibitor discovered to enhance the effectiveness
of radiation therapy in a non-toxic manner. This compound is designed
to dramatically reduce the frequency and dose of radiation therapy
through a unique mechanism of action which gently disables cellular
DNA repair mechanisms without interfering with p53 pathways.
LDL4-L10
is a novel set of compounds discovered that have proven in vitro
to antagonize the interaction between PCSK9 and LDLR for the treatment
of hypercholesterolemia.
AD-L06 is
a novel set of compounds under development for the prevention of
inflammatory response in the brain believe by the company to be
at the heart of Alzheimer's Disease.
RVI-L08 is
a novel retroviral integrase inhibitor that safely prohibits the
multimerization of the highly conserved integrase enzyme used by
many human retroviruses including HIV. This multimerization process
is critical to the integration of viral genetic material with the
DNA of the infected host cell.
|
